DR PHARMA
Annual accounts 2025
micro format, filed on 10-06-2026, 51 days before the deadlineThe turnover shown is an estimate from the gross margin.
Turnover ≈ €370,000. Estimated: probably between €260,000 and €690,000.
Balance sheet
balance sheet total €2.1m on 31-12-2025in euro
in euro
Position in the sector
27.6%
Higher than 45% of 22,939 companies in 2025.
0.04
Lower than 95% of 22,068 companies in 2025.
5.2%
Higher than 55% of 22,218 companies in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: bottom quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
2.1m | 2.1m | 2.1m | 2.1m | |
21/28 |
2.1m | 2.1m | 2.1m | 2.1m | |
28 |
2.1m | 2.1m | 2.1m | 2.1m | |
29/58 |
20,627 | 5,950 | 6,113 | 17,744 | |
29 |
- | - | - | 249 | |
290 |
- | - | - | 249 | |
40/41 |
- | - | - | 284 | |
40 |
- | - | - | 0 | |
41 |
- | - | - | 284 | |
54/58 |
18,670 | 4,082 | 4,333 | 17,211 | |
490/1 |
1,957 | 1,868 | 1,780 | - | |
| Balance sheet: equity and liabilities | |||||
10/49 |
2.1m | 2.1m | 2.1m | 2.1m | |
10/15 |
591,990 | 479,821 | 170,620 | 48,063 | |
10/11 |
5,000 | 5,000 | 5,000 | 5,000 | |
14 |
586,990 | 474,821 | 165,620 | 43,063 | |
17/49 |
1.6m | 1.7m | 2.0m | 2.1m | |
17 |
1.0m | 1.2m | 1.3m | 1.4m | |
170/4 |
1.0m | 1.2m | 1.3m | 1.4m | |
42/48 |
506,906 | 464,019 | 654,144 | 650,017 | |
42 |
138,871 | 137,207 | 135,515 | 133,938 | |
44 |
1,222 | 305 | 31 | 28,875 | |
440/4 |
1,222 | 305 | 31 | 28,875 | |
45 |
38,441 | 35,347 | 37,437 | 12,000 | |
450/3 |
28,681 | 25,586 | 27,437 | - | |
454/9 |
9,760 | 9,760 | 10,000 | 12,000 | |
47/48 |
328,371 | 291,160 | 481,160 | 475,204 | |
492/3 |
16,461 | 17,969 | - | - | |
| Income statement | |||||
9900 |
120,788 | 118,554 | 126,504 | 91,172 | |
640/8 |
1,483 | 1,610 | 3,136 | - | |
9901 |
119,306 | 116,944 | 123,368 | 91,172 | |
75/76B |
50,000 | 250,000 | 51,761 | - | |
75 |
50,000 | 250,000 | 51,761 | - | |
65/66B |
33,893 | 37,554 | 21,679 | 48,109 | |
65 |
33,893 | 37,554 | 21,679 | 48,109 | |
9903 |
135,413 | 329,390 | 153,449 | 43,063 | |
67/77 |
23,244 | 20,189 | 30,891 | - | |
9904 |
112,169 | 309,201 | 122,557 | 43,063 | |
9905 |
112,169 | 309,201 | 122,557 | 43,063 | |
| Appropriation of the result | |||||
9906 |
586,990 | 474,821 | 165,620 | 43,063 | |
14P |
474,821 | 165,620 | 43,063 | - | |
| Document | |||||
The notes to these accounts have 3 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 10-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| - | - | 2,800 | 2.1m | ||
| 14,589 | -252 | -12,878 | - | ||
| -486,279 | -458,069 | -648,031 | -632,273 | ||
| 27.6% | 22.5% | 8.0% | 2.2% | ||
| 0.04 | 0.01 | 0.01 | 0.03 | ||
| 2.63 | 3.45 | 11.51 | 43.58 | ||
| 18.9% | 64.4% | 71.8% | 89.6% | ||
| 5.2% | 14.5% | 5.7% | 2.0% |
EBIT margin: not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Financial fixed assets | - | - | €2,800 | €2.1m |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Insights on DR PHARMA
The operating result for 2025 is 2% higher than in 2024. It is a recovery after the fall in 2024.
Debt's share of the balance-sheet total falls from 77.5% to 72.4%. Equity is higher and debt is lower.